@article {Morosoli2021.11.18.21266388, author = {Federico Morosoli and Sandra Hunziker and Kathrin Zuercher and Anne Tscherter and Sebastian Grunt and on behalf of the Swiss Cerebral Palsy Registry Group}, title = {Prescription Practices of Medical Cannabinoids in Children with Cerebral Palsy - A Survey of the Swiss Cerebral Palsy Registry}, elocation-id = {2021.11.18.21266388}, year = {2021}, doi = {10.1101/2021.11.18.21266388}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Aim Medical cannabinoids are prescribed to children with cerebral palsy despite limited evidence. We aimed to assess the prescription practices of cannabinoids in children with cerebral palsy with a particular focus on indications and preparations used and how well cannabinoids are tolerated. Furthermore, we investigated how physicians acquire knowledge on cannabinoid medication.Methods We asked physicians with expertise in the care of children with CP on their prescription practices of medical cannabinoids. Data was collected through an online survey, which was distributed by email. In addition to the demographic information of participants, we also inquired about the indications for the prescription of cannabinoids, about experiences regarding efficacy and the observed side effects of the therapy.Results Seventy physicians from Europe, North America and Australia completed the survey. Forty-seven participants were experienced in the treatment of children with cerebral palsy by cannabinoids. The most common indication was epilepsy (69\%), followed by spasticity (64\%) and pain (63\%). The prescribed preparations and doses varied considerably. Half of the participants evaluated the effect of the medical cannabinoids as moderate. Twenty-nine physicians reported side effects, most frequently in the form of drowsiness (26\%), somnolence (19\%), fatigue (13\%), and diarrhoea (13\%).Conclusions Despite the lack of evidence to date, medical cannabinoids are used to treat children with cerebral palsy in a wide variety of indications. Randomized controlled trials in this vulnerable patient group are therefore of utmost importance.Highlights- Cannabinoids are frequently used in children with CP, despite weak evidence.- Cannabinoids are prescribed in children with CP for different indications.- The most common indications are epilepsy, spasticity, and pain.- Common acute side effects are drowsiness, somnolence, fatigue, diarrhoea, and nausea.- Long-term side effects of cannabinoids in children with CP were not observed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Nevertheless, we would like to thank the Swiss Foundation for Cerebral Palsy Children and the Anna Mueller Grocholski Foundation. Their support of the Swiss Cerebral Palsy registry laid the foundation for this survey. The funders of the Swiss Cerebral Palsy Registry did not play a role in the conduct of this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a survey of the Swiss cerebral palsy registry (Swiss-CP-Reg). In 2017, Swiss-CP-Reg obtained authorisation from the Cantonal Ethics Committee of Bern (2017-00873, risk category A, observational study) to collect national medical data from hospitals, clinics, and private practices, self-reported data from patients and families, to link data, and to retrospectively register deceased patients and patients lost to follow-up from clinics. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAbbreviations:CBDcannabidiolCPCerebral palsyRCTrandomized controlled trialTHCtetrahydrocannabidiol;}, URL = {https://www.medrxiv.org/content/early/2021/11/21/2021.11.18.21266388}, eprint = {https://www.medrxiv.org/content/early/2021/11/21/2021.11.18.21266388.full.pdf}, journal = {medRxiv} }